The Phase I clinical trial of CAR-GPC3 T cells, sponsored by Zhejiang University, targets advanced hepatocellular carcinoma (HCC) patients who are not suitable for surgery or have progressed after standard therapies. This innovative approach leverages a 4th generation CAR-T cell technology, which may provide a competitive edge in the CAR-T landscape, particularly in solid tumors like HCC. The market for HCC therapies is expanding, driven by rising incidence rates and the need for effective treatments in advanced stages. The trial's completion suggests readiness for further development, potentially attracting interest from pharmaceutical partners or investors. The collaboration with CARsgen Therapeutics Co., Ltd. indicates a strategic industry partnership that may enhance commercialization prospects.